Dr. Tang Suoqin is a Distinguished Professor and Senior Consultant in the Department of Hematology and Oncology at Beijing Jingdu Children’s Hospital, a leading institution in pediatric hematologic and solid tumor care in China. With over 30 years of clinical and academic leadership, he has become a pivotal figure in advancing the treatment of high-risk neuroblastoma and refractory pediatric solid tumors.
Dr. Tang’s career trajectory is marked by international collaboration and institutional transformation. After serving as Director of Pediatrics at the People’s Liberation Army General Hospital (PLAGH), he joined Beijing Jingdu Children’s Hospital in the 2010s, contributing to its rise as a top-tier private pediatric center. His early work in the 1990s included a three-year fellowship (1993–1996) at the Children’s Hospital Los Angeles (CHLA), where he trained under Dr. Stuart Siegel, a pioneer in pediatric oncology. This experience profoundly shaped his patient-centric philosophy and expertise in neuroblastoma research .
A vocal advocate for private hospital development in China, Dr. Tang believes these institutions are critical to meeting personalized healthcare demands and bridging gaps in specialized pediatric oncology care.
Master’s Degree in Pediatrics, Chinese PLA Medical School.
Fellowship in Pediatric Oncology, Children’s Hospital Los Angeles (CHLA), University of Southern California (1993–1996)
Focus: Neuroblastoma pathogenesis and multimodal therapy protocols
Visiting Scholar, CHLA Cancer and Blood Disease Center (mentored by Dr. Stuart Siegel)
Dr. Tang specializes in high-risk pediatric malignancies, with a dual emphasis on translational research and multidisciplinary care:
1. Solid Tumors:
Neuroblastoma: Achieved a 20-year survival milestone in stage IV cases through optimized chemotherapy/immunotherapy combinations .
Rhabdomyosarcoma & Wilms’ Tumor: Integrated surgery, radiation, and targeted therapies to reduce relapse rates.
2. Hematologic Disorders:
Leukemia/Lymphoma: Refractory/relapsed cases, with expertise in hematopoietic stem cell transplantation (HSCT).
Bone Marrow Failure Syndromes: Severe aplastic anemia, myelodysplastic syndromes (MDS) .
3. Innovative Approaches:
Championed international protocol adaptation, incorporating U.S.-derived regimens into Chinese clinical workflows.
Member of the Children's Oncology Group (COG), USA
Recipient of the Chinese Pediatrician Award (the highest national honor in pediatrics)
Standing Committee Member of the Pediatric Branch of the Chinese Medical Association (12th-15th terms)
Director of the Precision Medicine Professional Committee of the Pediatric Branch of the Chinese Medical Association
Member of the Expert Committee on Children's Hematologic Diseases of the National Health Commission
First Prize in the Excellent Young Scientist Paper Competition of the Chinese Medical Association
Second Prize of the PLA Medical Achievement Award
Neuroblastoma Pathobiology: Identified molecular markers for risk stratification and therapy personalization .
Multicenter Clinical Trials: Led national studies on salvage HSCT and CAR-T therapy for relapsed solid tumors.
Health Systems Research: Analyzed private-public hospital collaboration models to improve pediatric oncology accessibility .
Funding Leadership: Principal Investigator for 2 National Natural Science Foundation General Programs and 2 National High-Tech R&D Program (863 Program) projects .
Mandarin (Native) / Fluent in English
With 100+ peer-reviewed papers (20+ SCI-indexed) and 7 academic monographs, Dr. Tang’s scholarly impact spans:
Key Books:
Clinical Management of Pediatric Neuroblastoma (chief editor, 2018)
Advances in Pediatric HSCT (co-editor, 2020) .
Seminal Studies:
"Long-term Outcomes of Stage IV Neuroblastoma: A 20-Year Follow-up Cohort" (Journal of Pediatric Hematology/Oncology, 2022) .
"CAR-T Therapy for Refractory Pediatric Solid Tumors: A Phase I/II Trial" (Nature Communications, 2024).
Policy Papers:
Authored white papers on private hospital roles in China’s pediatric oncology framework for the National Health Commission.
Dr. Tang Suoqin epitomizes the fusion of clinical mastery, global scholarship, and healthcare advocacy. By bridging U.S.-China oncology innovations and empowering private hospitals, he has redefined survival paradigms for pediatric solid tumors. His ongoing work on AI-driven precision oncology platforms aims to democratize access to cutting-edge therapies across China.
Overall Rating: Consistently rated 4.9/5 on Haodf.com (China’s leading medical platform), with praise for:
Compassionate Communication: Parents highlight his ability to explain complex treatments in accessible terms.
Long-term Follow-up: Families appreciate his proactive post-discharge monitoring via telehealth platforms.
Testimonial Excerpts:
"Dr. Tang gave us hope when others said there was none. My daughter is now cancer-free for 5 years." (Mother of neuroblastoma survivor, 2023) .
"His international connections ensured our son received the latest immunotherapy." (Father of leukemia patient, 2024).
EN
CN
